Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.

This was the stock's second consecutive day of losses.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Matteo Paz built a machine-learning algorithm in high school to analyze heaps of data for NASA. He just won a $250,000 ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

In an opinion that may complicate the U.S. Department of Justice’s (“DOJ”) efforts to enforce the False Claims Act (“FCA”), the U.S. Court of ...

Although sometimes overshadowed by the all-important income statement, the balance sheet can offer essential insights into a ...

The winners of one of the nation's oldest science contests were revealed late Tuesday — and a Philly student took home one of ...

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...

Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

Recent legal and political False Claims Act (“FCA”) developments signal a potentially turbulent time for the defense of investigations and ...

Dr. Matthew Anderson was appointed co-director of the Oxford-Harrington Rare Disease Centre, a partnership between the ...